Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPhan, Kevin-
dc.contributor.authorDmytriw, Adam A-
dc.contributor.authorMaingard, Julian-
dc.contributor.authorAsadi, Hamed-
dc.contributor.authorGriessenauer, Christoph J-
dc.contributor.authorNg, Wyatt-
dc.contributor.authorKewagamang, Kitso-
dc.contributor.authorMobbs, Ralph J-
dc.contributor.authorMoore, Justin M-
dc.contributor.authorOgilvy, Christopher S-
dc.contributor.authorThomas, Ajith J-
dc.identifier.citationWorld Neurosurgery 2017; 108: 850-858.e2-
dc.description.abstractBACKGROUND: To date, no randomized trial has directly addressed the question of whether intravenous (IV) tissue plasminogen activator (tPA) improves outcomes in IV tPA-eligible patients who will eventually undergo endovascular therapy (EVT), or whether a direct EVT strategy is equally effective. We performed a systematic review and meta-analysis to compare the efficacy and safety of direct EVT versus endovascular treatment with IV tPA (EVT+IV tPA) in adults with acute ischemic stroke. METHODS: We performed electronic searches of 6 databases from their inception to January 2017. Data were extracted and analyzed according to predefined clinical endpoints. RESULTS: Twelve comparative studies, comprising 1275 patients in the EVT-only arm and 1340 patients in the combined EVT+IV tPA arm, were included. The rates of good functional outcomes (modified Rankin Scale score ≤2) and 90-day mortality were not statistically significantly different between the EVT and EVT+IV tPA arms (44% vs. 48%; odds ratio [OR], 0.80; 95% confidence interval [CI], 0.64-1.002; P = 0.052 and 20.4% vs. 19.4%, OR 1.19; 95% CI, 0.83-1.71; P = 0.34, respectively). The rate of symptomatic intracranial hemorrhage also was not significantly different between the EVT and EVT+IV tPA arms (3.7% vs. 3.8%; OR, 0.98; 95% CI, 0.65-1.48; P = 0.91). There were no between-group differences in the rates of other complications. CONCLUSIONS: No significant differences between the 2 groups were found in terms of favorable functional outcome, mortality rate, or complications based on contemporary endovascular therapies.-
dc.subjectAcute ischemic Stroke-
dc.subjectStent retriever-
dc.subjectTissue plasminogen activator-
dc.titleEndovascular Thrombectomy Alone versus Combined with Intravenous Thrombolysis.-
dc.typeJournal Article-
dc.identifier.journaltitleWorld Neurosurgery-
dc.identifier.affiliationNeuroSpine Surgery Research Group, Sydney, Australiaen
dc.identifier.affiliationInterventional Neuroradiology Service, Department of Radiology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDivision of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USAen
dc.identifier.affiliationSchool of Medicine, Faculty of Health, Deakin University, Waurn Ponds, Australiaen
dc.identifier.affiliationInterventional Neuroradiology Unit, Monash Imaging, Monash Health, Melbourne, Australiaen
dc.type.austinComparative Study-
dc.type.austinJournal Article-
dc.type.austinReview-, Hamed
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 21, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.